Boehringer Ingelheim and MiNA Therapeutics to Develop Novel Treatment Approaches for Fibrotic Liver Diseases
Boehringer Ingelheim and MiNA Therapeutics (“MiNA”), a pioneer in RNA activation therapeutics, today announced that they have signed a collaboration and licensing agreement focused on the development of novel compounds to treat fibrotic liver diseases such as NASH, based on MiNA’s small activating RNA (“saRNA”) therapeutics platform. The new partnership underscores Boehringer Ingelheim’s commitment to advancing innovative new treatment approaches and furthering its comprehensive clinical offerings in cardiometabolic diseases. It combines MiNA’s leading expertise in the development of saRNAs with Boehringer Ingelheim’s experience in bringing first-in-class breakthrough treatments to patients with cardiometabolic disease.
NASH is a major cause of liver fibrosis and cirrhosis and an area of high unmet medical need. It has an especially high prevalence among obese and diabetic patients and currently there are no treatments available. NASH is expected to become the most common cause of advanced liver disorders eventually necessitating liver transplantation in the coming decades.
saRNAs have been demonstrated to activate transcription of specific genes resulting in upregulation of proteins with therapeutic potential. In the new collaboration, Boehringer Ingelheim and MiNA aim to identify targets to restore metabolic functionality of hepatocytes and prevent fibrotic tissue formation in patients with NASH. It will enable Boehringer Ingelheim to rapidly design, profile and develop novel compounds, potentially also creating opportunities for combination with Boehringer Ingelheim’s other NASH-pipeline assets.
“This collaboration is a recognition of our platform and expertise in liver-based diseases as well as validation from an established pharmaceutical leader in what has been an exciting year for the company,” said Robert Habib, CEO of MiNA.
“This new collaboration is another sign of our ongoing commitment to patients with cardio-metabolic diseases, including NASH,” said Clive R. Wood, Ph.D., Corporate Senior Vice President Discovery Research at Boehringer Ingelheim. “It will combine MiNA’s pioneering work with saRNAs with our expertise in biopharmaceutical research and development,” added Wood.
Boehringer Ingelheim has a long history of excellence in the discovery and development of medicines for cardiometabolic disease patients. It has established a broad portfolio of marketed products for thromboembolic diseases, type 2 diabetes, acute myocardial infarction, hypertension and cardio-renal risk reduction. The cardiometabolic diseases pipeline extends beyond type 2 diabetes and anticoagulation with a focus on innovative drugs for the treatment of the devastating consequences of diabetes as well as contributing factors like obesity.
Under the terms of the agreement, MiNA will receive an upfront payment and committed research funding as well as potential research, development and regulatory milestone payments totalling up to EUR 307 million. In addition, MiNA is entitled to up to double-digit royalties on sales of selected products resulting from the partnership. No further financial details have been disclosed.
In this agreement, MiNA was advised by Ferghana Partners and Taylor Wessing LLP.
Please click on the link below for ‘Notes to Editors’:
Contact for MiNA Therapeutics:
Dr. Stephanie May
MacDougall Biomedical Communications
P: +49 89 2424 3494 :: M: +49 175 571 1562
Contacts for Boehringer Ingelheim:
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim GmbH
P: +49 6132 77-90815 :: M: + 49 151 150 20 690
Associate Director, Media and Corporate Reputation
Boehringer Ingelheim Pharmaceuticals, Inc.
P: +1 203 791-6672 :: M: +1 203-957 5114
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Telstra and Sigma Systems to Present Catalog-Driven Dynamic Offer Creation at TM Forum Live! Asia21.11.2017 13:00 | Tiedote
Sigma Systems, the global leader in catalog-driven software, announced today that it will be presenting at TM Forum Live! Asia in partnership with Telstra, Australia’s leading telecommunications and technology company. Sigma’s Chief Technology Officer (CTO), Catherine Michel, will be on stage with Telstra's Chief Technology Officer (Customer), Dr. Fawad Nazir, to discuss why traditional service providers must adopt a “digital native” mindset and the corresponding operational agility to thrive in a digital economy. The ability to create and launch new offers in minutes, rather than months, and rapidly enable new business models is critical to an operator’s success. “Sigma Catalog creates the ability to sell through and then orchestrate the fulfillment of an order from different channels into the full B/OSS stack and across various delivery networks. The product’s Offer Canvas
Seoul Semiconductor First in the World to Receive Low Risk Eye Safety Certification for its Natural Light LED SunLike21.11.2017 12:00 | Tiedote
The world-leading LED company Seoul Semiconductor (Head office: Ansan-si, Korea, CEO: Chung Hoon Lee, hereinafter Seoul Semiconductor) announced that SunLike, which implements light which comes closest to sunlight, received an RG-1 Eye Safety certification based on the safety of its light source and was recognized for the highest level of safety amongst 25W COB type LED. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171121005036/en/ 25W SunLike light source which acquired RG-1 grade in Eye Safety certification (Photo: Business Wire) Eye Safety certification is a rating based on safety from analyzing the LED wavelengths. In Europe, where top priority is placed on the safety of lighting, Eye Safety certification is essential and the light source must be higher than RG-3 level, otherwise eye sight may b
FlexTrade Introduces Enhanced Cross-OMS Aggregation for MiFID II21.11.2017 12:00 | Tiedote
FlexTrade Systems (@FlexTrade), a global leader in cross-asset execution and order management systems, today announced the rollout of an enhanced version of its multi-OMS aggregation functionality, an in-built feature of the FlexTRADER EMS, which allows users to merge and net orders across multiple OMSs regardless of the underlying version or implementation. “With a number of major asset manager mergers over the past few years bringing together a variety of OMS technologies, we have seen a surge of interest in FlexTRADER’s unique abilities in cross-OMS order aggregation,” said Oliver Boatfield, EMEA Sales Director at FlexTrade UK. Along with the ability to dynamically merge orders within and across OMSs, FlexTRADER provides highly configurable allocation logic with several out-of-the-box rules, including LIFO, FIFO, pro-rata and optimal average pricing. I
Starr Companies Announces Aviation Insurance Agreement with SMARTT MGA21.11.2017 11:00 | Tiedote
Starr Companies today announced an agreement with SMARTT MGA to act as Agents for Starr International (Europe) Limited to provide automated quotes and policy documentation for light general aviation business. “We have built a close and fruitful relationship with SMARTT and are happy that we have formalized this arrangement,” stated Jim Herbert, chief underwriting officer, aviation. “We believe our StarrLink International platform will bring significant efficiencies to the way aviation business is placed. We look forward to expanding our product offerings through SMARTT MGA in the near future.” Michal Chmielewski, chief executive officer, SMARTT MGA, stated, “Most quotes, binding and policy documentation issuance take only a few minutes to produce through the StarrLink platform – changing the way aviation insurance is purchased.” SMARTT MGA is a part of SMARTT Grou
Octapharma Donates 30.5 Million International Units of Its Medicine Nuwiq to Treat People with Haemophilia in Developing Countries21.11.2017 11:00 | Tiedote
2017: Octapharma is pleased to announce the completion of a charitable donation of 30.5 million international units of its human cell-line derived recombinant factor VIII product, Nuwiq®, in collaboration with Project SHARE, North Andover, Massachusetts (USA). This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171121005038/en/ Donation in Nepal of human cell-line derived recombinant factor VIII product Nuwiq (Photo: Business Wire) Up to 75% of the world's estimated 400,000 people with haemophilia have little or no access to treatment that resolves life- and limb-threatening bleeds, and enables surgery and rehabilitation. A humanitarian program, Project SHARE facilitates the donation of blood-clotting factor products for the treatment of people with haemophilia in need of factor replacement therapy
"Complete Your Game!"The 13th Global Game Exhibition G-STAR 2017 Opens to Success21.11.2017 06:39 | Tiedote
The start of the G-STAR Game Show and Trade All Round 2017, an international game exhibition that examines the global gaming industry and its future possibilities, was announced at BEXCO, Busan, on November 16th. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171120006218/en/ Opening Ceremony of G-STAR 2017 (Photo: Business Wire) Celebrating its 13th anniversary this year, G-STAR 2017 is hosted by the Korea Game Industry Association (K-GAMES) and co-organized by the G-STAR Organizing Committee and the Busan IT Industry Promotion Agency. It runs for 4 days from the 16th to 19th (Sun). This year’s G-STAR 2017 has been a record success, bringing together 693 companies from 35 countries and exhibiting 2,857 booths - a 5.0% increase from the previous year. G-STAR 2017
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme